Production of siRNA-Loaded Lipid Nanoparticles using a Microfluidic Device
March 22nd, 2022
10.6K views
Microfluidic-based lipid nanoparticle (LNP) production methods have attracted attention in drug delivery systems (DDSs), including RNA delivery. This protocol describes the fabrication, LNP (siRNA-loaded LNP) production, and LNP evaluation processes using our original microfluidic device named iLiNP.
Overview
This article presents a protocol for the production of siRNA-loaded lipid nanoparticles (LNPs) using a microfluidic device called iLiNP. The method allows for precise control over LNP size, which is crucial for effective drug delivery systems.
Key Study Components
Area of Science
- Drug delivery systems
- Lipid nanoparticles
- Microfluidics
Background
- Lipid nanoparticle size influences biodistribution and therapeutic efficacy.
- Control of LNP size is essential for optimizing RNA delivery.
- The iLiNP device enables size control from 20 to 100 nanometers.
- Electrostatic interactions facilitate siRNA encapsulation in LNPs.
Purpose of Study
- To develop a reliable method for producing siRNA-loaded LNPs.
- To evaluate the impact of LNP size on gene silencing efficiency.
- To optimize flow conditions for desired LNP characteristics.
Methods Used
- Preparation of lipid and aqueous solutions for LNP production.
- Use of the iLiNP device for mixing and LNP formation.
- Dialysis of LNP suspensions to remove excess materials.
- Dynamic light scattering to measure LNP size and distribution.
Main Results
- The iLiNP device produced siRNA-loaded LNPs with a size of 90 nanometers and 95% encapsulation efficiency.
- Small LNPs were formed under high total flow rate conditions.
- siRNA-loaded LNPs demonstrated cytotoxicity and effective gene silencing.
- Optimized flow conditions were critical for achieving desired LNP sizes.
Conclusions
- The microfluidic method using the iLiNP device simplifies LNP production.
- This approach is expected to standardize LNP production in research.
- Further studies can explore the application of this method in various RNA delivery systems.
Frequently Asked Questions
What is the significance of LNP size in drug delivery?
LNP size affects biodistribution, therapeutic efficacy, and gene silencing performance.
How does the iLiNP device control LNP size?
The device allows for precise adjustments in flow rates, enabling size control from 20 to 100 nanometers.
What is the encapsulation efficiency of siRNA in LNPs?
The encapsulation efficiency achieved is 95% due to electrostatic interactions.
What are the main components used in LNP production?
Key components include DOTAP, DSPC, cholesterol, and DMG-PEG2k.
What are the cytotoxic effects of siRNA-loaded LNPs?
Cytotoxicity was observed at doses ranging from 10 to 100 nanomolar siRNA.
How are LNPs evaluated after production?
LNPs are evaluated for size, size distribution, and poly dispersity index using dynamic light scattering.
Executive Industry Relevance
Precise control of lipid nanoparticle (LNP) size is critical for optimizing biodistribution, therapeutic efficacy, and gene silencing performance in RNA-based drug delivery systems. The iLiNP microfluidic device enables reproducible LNP production with tunable size from 20 to 100 nanometers, supporting early-stage target validation and lead identification workflows. This capability enhances predictive confidence in preclinical models by reducing variability in nanoparticle performance, a key factor in de-risking translational advancement.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of size-dependent biological activity for siRNA-loaded LNPs in target validation assays.
- Operational Value: Provides standardized LNP formulations to reduce noise in phenotypic screening and mechanistic de-risking studies.
Screening & Assay Development
- Scientific Value: Generates monodisperse siRNA-LNPs with defined size and 95% encapsulation efficiency for reliable compound evaluation.
- Operational Value: Supports assay standardization through reproducible LNP size control via flow rate adjustment in the iLiNP device.
Translational & Preclinical Research
- Scientific Value: Facilitates correlation of LNP size with gene silencing efficiency and cytotoxicity in disease-relevant systems.
- Operational Value: Enables scalable production of mRNA, siRNA, and ribonucleoprotein-loaded LNPs for preclinical continuity.
Pipeline & Workflow Integration
The iLiNP microfluidic method fits within the discovery continuum from early target validation through lead identification to preclinical development, particularly for RNA therapeutics where size-dependent delivery impacts efficacy.
- Discovery Biology: Supports hypothesis testing by enabling systematic variation of LNP size to assess impact on cellular uptake and target engagement.
- Screening: Delivers assay-ready LNP formulations with consistent size distribution and high siRNA encapsulation for reproducible compound screening.
- Analytics: Provides quantitative size, polydispersity, and zeta potential outputs via dynamic light scattering to inform go/no-go decisions.
- Translational Research: Connects discovery-phase LNP optimization to preclinical evaluation through standardized size-controlled nanomedicines.
- Enterprise Reuse: Establishes a reusable platform for producing various RNA-loaded LNPs (siRNA, mRNA, RNP) across multiple projects.
Operational & Enterprise Impact
- Scientific Value: Improves target confidence by linking LNP physicochemical properties to functional outcomes like gene silencing.
- Operational Value: Enhances reproducibility and scalability of LNP production through microfluidic precision.
- Strategic Value: Reduces late-stage biological risk by enabling early de-risking of delivery vehicle performance.
- Portfolio Impact: Informs risk-adjusted prioritization of RNA therapeutic candidates based on delivery efficiency.
Implementation Considerations
- Requires expertise in lipid formulation, microfluidic handling, and nucleic acid loading.
- Depends on syringe pumps, glass syringes, and dialysis infrastructure for LNP purification.
- Necessitates standardization of flow rate ratios and total flow conditions across teams.
- Involves adaptation considerations when changing lipid compositions or RNA cargo types.
- Limited by the need for post-production dialysis and dynamic light scattering for quality control.
Biopharma FAQs
Why does LNP size matter for target validation in siRNA studies?
LNP size influences cellular uptake, biodistribution, and gene silencing efficiency, making it a critical variable in validating siRNA targets. Controlling size from 20 to 100 nanometers enables researchers to isolate the delivery variable from the siRNA sequence effect. This supports more accurate assessment of target engagement and phenotypic outcomes in discovery assays.
How does flow rate ratio isolation support discovery pipeline decisions?
The iLiNP device uses flow rate ratio (FRR) to control LNP size independently of total flow rate, enabling precise manipulation of nanoparticle characteristics. Isolating FRR as an independent variable allows teams to study size-dependent effects on encapsulation, stability, and activity. This supports data-driven go/no-go decisions in lead identification by de-risking delivery performance early.
What quantitative measurements enable LNP screening readiness?
Dynamic light scattering provides LNP size, size distribution, and polydispersity index as key quality attributes for screening readiness. These measurements ensure batch-to-batch consistency in siRNA-loaded LNPs used across assays. The 90-nanometer size and narrow distribution reported indicate suitability for standardized compound evaluation workflows.
Why are replication requirements important for cross-functional collaboration?
Reproducible LNP size control via the iLiNP device ensures that formulation scientists, biologists, and analytical teams work with identical nanoparticle preparations. Replication under defined flow conditions (e.g., FRR 5) yields consistent 90-nanometer siRNA-LNPs with 95% encapsulation efficiency. This alignment reduces variability in functional readouts like cytotoxicity and luciferase silencing across departments.
What statistical analysis capabilities are required before implementing LNP size control?
Teams must be able to analyze dynamic light scattering data for size, polydispersity, and distribution to assess LNP homogeneity. Comparing size outcomes across flow rate ratios (e.g., FRR 3 vs FRR 5) requires comparative statistical evaluation to confirm significant differences. This analytical capability ensures that observed size changes are robust and not due to technical noise before adoption in decision-making.
Chapters in this video
0:04
Introduction
0:54
Preparation of Lipid Solutions and the siRNA/ Buffer Solution
1:58
Set-Up of the iLiNP Device and Production of LNPs
2:35
Dialysis of the LNP Suspension and LNP Size Measurement
3:24
Results: POPC LNP Size Distributions Produced by the iLiNP Device at Different Flow Rate Ratios and Characterization and Cytotoxicity of siRNA-Loaded LNPs
5:22
Conclusion
